Editorial response: Staphylococci vs. glycopeptides - How much are the battle lines changing?

Clinical Infectious Diseases

Volumn 29, Issue 4, 1999, Pages 768-770

  Moellering Jr , Robert C ^a,b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPEPTIDE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIUM ISOLATE; EDITORIAL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS;

EID: 0343415172     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520430     Document Type: Editorial

References (22)

1. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-23.
2. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501.
3. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J Med 1999;340:556-7.
4. Moellering RC Jr. Vancomycin-resistant enterococci. Clin Infect Dis 1998;26:1196-9.
5. Woodford NN, Johnson AP, Morrison D, Speller DCE. Current perspectives on glycopeptide resistance. Clin Microbiol Rev 1995;8:585-615.
6. Nobel WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992;72:195-8.
7. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin-susceptibility. J Antimicrob Chemother 1997;40:135-6.
8. Rotun SS, McMath V, Schoonmaker DJ, et al. Staphylococcus aureus with reduced susceptibility to vancomycin isolated from a patient with fatal bacteremia. Emerg Infect Dis 1999;5:147-9.
9. Poly MC, Grelaud C, Martin C, de Lumley L, Denis F. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital [letter]. Lancet 1998;351:1212.
10. Howe RA, Bowker KE, Walsh TR, Feest TG, MacGowan AP. Vancomycin-resistant Staphylococcus aureus. Lancet 1998;351:601-2.
11. Wong SSY, Ho PL, Woo PCY, Yuen KY. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance. Clin Infect Dis 1999;29:760-7.
12. Geraci JE. Some laboratory and clinical experiences with a new antibiotic, vancomycin. In: Antibiotic Annual 1955-1956. New York: Medical Encyclopedia, 1956:90-106.
13. Ziegler DW. Vancomycin, a new antibiotic. II. In vitro antibacterial studies. In: Antibiotic Annual 1955-1956. New York: Medical Encyclopedia, 1956:612-8.
14. Sieradzki K, Tomasz A. Suppression of glycopeptide resistance in a highly teicoplanin-resistant mutant of Staphylococcus aureus by transposon inactivation of genes involved in cell-wall synthesis. Microb Drug Resist 1998;4:159 68.
15. Chuard C, Vaudaux P, Waldvogel FA, Lew DP. Susceptibility of Staphylococcus aureus growing on fibroncctin-coated surfaces to bactericidal antibiotics. Antimicrob Agents Chemother 1993;37:625-32.
16. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med 1991;115:674-80.
17. Moellering RC Jr, Krogstad DJ, Greenblatt DJ. Pharmacokinetics of vancomycin in normal subjects and in patients with reduced renal function. Rev Infect Dis 1981;3:230-5.
18. Schwalbe RS, Stapleton JT, Gilligan PH. Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987;316:927-31.
19. Mainardi JL, Shlaes DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibility of methicillin-resistant strains of Staphylococcus aureus. J Infact Dis 1995;171:1646-50.
20. Moreira B, Boyle-Vavra S, de Jonge BLM, Daum RS. Increased production of penicillin-binding protein 2, increased detection of other penicillin-binding proteins, and decreased coagulase activity associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob Agents Chemother 1997;41:1788-93.
21. Tenover FC, Lancaster MV, Hill BC, et al. Characterization or staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-7.
22. Hanaki H, Labischinski H, Inaba Y, Kondo N, Murakami H, Hiramatsu K. Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50. J Antimcrob Chemother 1998;42:315-20.